Humacyte Leadership to Present at Credit Suisse 30th Annual Healthcare Conference
Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology company, announced that CEO Laura Niklason will present at the Credit Suisse 30th Annual Healthcare Conference on Nov. 10, 2021, at 1 p.m. EST. The presentation will be available for replay for 30 days post-event. Humacyte focuses on developing universally implantable bioengineered human tissue to enhance patient care. Its human acellular vessels (HAVs) are in late-stage trials for various vascular applications and were the first to receive the FDA’s Regenerative Medicine Advanced Therapy designation.
- None.
- None.
DURHAM, N.C., Nov. 09, 2021 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that Laura Niklason, M.D., Ph.D., Chief Executive Officer, will present at the Credit Suisse 30th Annual Healthcare Conference taking place virtually, on Nov. 10, 2021, at 1 p.m. EST.
The webcast will be available for replay for at least 30 days following the presentation at https://humacyte.gcs-web.com/news-events/events-and-presentations.
About Humacyte
Humacyte, Inc., (Nasdaq: HUMA) is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
Humacyte Investor Contact:
investors@humacyte.com
Humacyte Media Contact:
media@humacyte.com
FAQ
What is Humacyte presenting at the Credit Suisse Healthcare Conference?
When will Laura Niklason's presentation at the Credit Suisse conference take place?
How can I access the Humacyte presentation after the event?
What is the focus of Humacyte's biotechnology platform?
What are the clinical applications of Humacyte's human acellular vessels?
